In 2009, graduated from Tianjin Medical University with a Ph.D. in immunology. In the same year, began to work in the Institute of Ophthalmology of Tianjin Medical University, where worked as a basic researcher. In 2012, went to Germany for a one-year postdoctoral research. Up to now, has undertaken and completed three national and provincial-level projects, and published a total of 66 research papers

Research Interest

Perez graduated from Facultad de Medicina at the Universidad de Antioquia, in Medellin, Colombia, S.A. in 1960. After a rotating Internship at Hospitals San Vicente de Paul in Medellin and Caldas he did a year Residency in Radiology at the Hospital Universitario, Cali, Colombia. He migrated to USA in June 1960 and received his training in Radiology and Radiation Oncology at Mallinckrodt Institute or Radiology, Washington University Medical School, St. Louis, MO (1960-1963) and was a Fellow in the Department of Radiation Therapy at M. D. Anderson Cancer Center in Houston, Texas (1963-1964). He was certified by the American Board of Radiology in 1964. He joined the Faculty at Washington University in Saint Louis in July 1964, was appointed Director of the Radiation Oncology Center in July 1976 and Chairman of the Department of Radiation Oncology in July 2001, a position he occupied until September 30, 2004. At the present time he is Professor Emeritus in the Department of Radiation Oncology. Perez served as President of the American Society of Therapeutic Radiation Oncology in 1982 and received the ASTRO Gold Medal in 1992, the American College of Radiology Gold Medal in 1997, the CRILA Gold Medal in 2003, the Janeway Gold Medal of the American Radium Society in 2003. In October 2006 Dr. Perez was awarded the National Cancer Fighter Award by the American College of Surgeons. Dr. Perez was a Trustee of the American Board of Radiology from 1985 through 1997. In 2011 he was awarded Honorary Membership in the European Society of Radiation Oncology (ESTRO) and in 2011 he received the Marie Curie Medal of the GEC-ESTRO. In 2013 he received the Gold Medal of the Spanish Society of Radiation Oncology (SEOR) and the same year he was awarded the Gold Medal of the Latin American Association of Radiation Oncology (ALATRO). Perez’ primary areas of professional interest are management of patients with carcinoma of the uterine cervix, carcinoma of the prostate and carcinoma of the breast. He also has a special interest in the management of patients with carcinoma of the head and neck, lung and other gynecologic malignancies. He is a prolific, highly published author with over 370 publications in refereed journals and 100 book chapters. Perez has served on the Editorial Board of several prestigious scientific Journals, including Cancer, the International Journal of Radiation Oncology, Biology and Physics, the American Journal of Clinical Oncology, Laryngoscope and Head and Neck Journal. Dr. Perez is co-editor with Dr. Luther W. Brady, Dr. Edward Halperin and Dr. David Wazer of Principles and Practice of Radiation Oncology, the sixth edition of which was published in the Spring of 2013 and the 7th edition is scheduled for publication in 2018. With Dr. William J. Hoskins and Dr. Robert Young, Dr. Perez was also co-editor of Principles and Practice of Gynecologic Oncology, the fourth edition of which was published in the fall of 2006. Dr. Perez co-edited a manual entitled Radiation Oncology: Management Decisions with Dr. K.S. Clifford Chao and Dr. Luther Brady; the third edition published in 2013. Dr. Perez also co-edited, Technological Basis of Radiation Therapy, 5th Edition, with Drs. S.H. Levitt, J.A. Purdy, and Philip Poortmans, published in October 2012. Recently he was Co-editor, with several colleagues from Chietti University, Italy, of a textbook on Delineation of Lymph nodes in Radiation Treatment Planning and Delineating Organs at risk in Radiation therapy.

Research Interest

Ali Fatemi-Ardekani is currently working in University of Mississippi as a trained and certified medical physicist, my clinical expertise includes Magnetic Resonance Imaging (MRI) and therapeutic radiation physics. My Ph.D. at McMaster University, Canada, was done under the guidance of Dr. Michael Noseworthy and Dr.Mark Haacke two world-renowned MRI physicists. My work focused on coding and optimization of a new high-resolution quantitative MRI pulse sequence called Susceptibility Weighted Imaging (SWI). This sequence has wide verities of clinical applications and research in different fields of medicine. That can be included; Quantitative detection of Traumatic brain injury (TBI), Stroke and hemorrhage, Sturge-Weber disease, Tumours, Multiple sclerosis, Vascular dementia, cerebral amyloid angiopathy (CAA) and Pneumocephalus. SWI allows the identification and characterization of hemorrhage and calcification in the human body quantitatively. We investigated to detect micro calcification in breast cancer. This project involved correlative imaging with CT allowing me to gain valuable practical experience in these modalities. Currently, SWI breast imaging is being applied in a clinical trial for detection of micro calcification quantitatively in suspicious breast cancer for women with dense breast tissue. Furthermore, the work has also led to the use of MRI for detecting sialoliths in salivary glands of young people, thus avoiding exposure to ionizing radiation from CT scanning. I was involved in many research activities including Magnetic Resonance quantitative tumor Imaging, cancer treatment post respond evaluations and MR guided Radiotherapy

Research Interest

Jorge Mario Blando is currently working in Anderson Cancer Center, he completed his Degree-Granting Education in National University of La Pampaand he completed his Postgraduate Training in Science Park-Research Division. He is having many experience in Immunopathology, Histology and Tissue Analysis Core. He has published over 22 books, 2 books, 50 abstracts.

Research Interest

Duaa Dakhlallah is currently working as Research Assistant Professor in West Virginia University. Her research focuses on the genetic mechanisms and regulatory pathways involved in pulmonary disease. In my graduate study I had focused on the role of microRNAs and epigenetic regulators in disease pathology. Specifically, we had identified alterations in gene regulation that correlates with clinical severity of disease in IPF. This has allowed us to target potential therapies, some of which have shown significant promise in our small animal models. While my current focus is on patients with IPF, these pathways allow diverse application too many fields of study. We have developed several collaborations with clinicians and researchers a like examining epigenetic regulation in diseases such as breast cancer, sepsis and acute respiratory distress syndrome. The central theme of my research is to identify epigenetic mechanisms by which prolonged macrophage survival can amplify the immune response and contribute to cancer, metastasis, Autophagy, chronic lung inflammation in idiopathic pulmonary fibrosis (IPF) and other inflammatory lung diseases ( sepsis) . Thus, my research focuses on two projects involving microvesicles and epigenetic regulation. We currently are examining the interplay of DNA methyltransferases and microvesicles in cancer and inflammation. We have several collaborative efforts with colleagues within the University and my former mentors as well with the Institute for Systems Biology. Beside, we are investigating how macrophages communicate via secreted microvesicles (MVs) which are taken-up by neighboring epithelium. Since July 2013 I was added to the Oncology T32, and had generated data demonstrating that MVs contain mRNAs coding the epigenetic regulating machinery, DNA methyltranferases (DNMTs) and histone deacetylases (HDACs), which regulate promoter CpG island methylation and resulting gene expression of tumor suppressor genes (TSGs) and genes driving epithelial-to-mesenchymal transition (EMT) in epithelial cells. This data was accepted as both a poster and short talk format for the 2014 AACR Cellular Heterogeneity in the Tumor Microenvironment in San Diego, CA February 26. Duaa will also be presenting this work in poster form at the OSUCCC – James 16th Annual Scientific Meeting on February 28. We have also established collaborations with experts in RNA-binding and chemical engineering to investigate aspects of miRNA/mRNA/protein packaging to the microvesicles. Thus, in summary, my funding and publication record underscores my technical capabilities and scientific achievements. As described in the proposal, our collaborative efforts on this proposal will enable us to perform preclinical testing of exciting new treatments for patients with breast cancer who otherwise have weak inefficient options clinically.

Research Interest

Peter Hu is an Associate Professor in the School of Health Professions (SHP) and is the Director of the Molecular Genetic Technology and the Graduate Diagnostic Genetics Programs. He received his Bachelor’s degree from Purdue University in 1990 with a major in Psychology and a minor in Chemistry. He later received his Master’s degree from Lamar University majoring in Microbiology and subsequently a Doctor of Philosophy from Trident University International (TUI) Healthcare Administration and Molecular Genetics. Dr. Hu also holds 3 specialty clinical certifications in Molecular Biology, Cytogenetics, and Clinical Laboratory Science. He joined MD Anderson Cancer Center (MDACC) in1995 and has worked in both clinical and academic environments. Dr. Hu has taught over 35 courses within the SHP and has served or is currently serving as Chair or as member on 45 institutional committees. Dr. Hu has published over 180 abstracts, 37 papers, 4 book chapters and edited a textbook. He is on the editorial board for 4 journals and a column editor for another. He has received 42 recognitions and awards during his tenure. Professionally, he has served as the President for Texas Association for Clinical Laboratory Science, Education Director and Chair of the Genetics Educators Committee for the Association for Genetic Technologist, Chair of the Molecular Scientific Assembly, Continuing Education Approval Committee, and Awards Subcommittee Chair for the American Society for Clinical Laboratory Science, Board of Directors and Executive Board of Director for National Accrediting Agency for Clinical Laboratory Sciences, and past President for the Association for Clinical Scientists. In addition, he has served as a clinical laboratory science programs inspector for the past 16 years. Dr. Hu regularly presents at state, national, and international levels on topics dealing with genetics research, clinical laboratory sciences, and education.

Research Interest

Research Interest

Research Interest

Research Interest

Dr Vasilev is board certified in Obstetrics and Gynecology and Gynecologic Oncology, with over 25 years of experience in treating women with gynecologic malignancies. He is currently Director of the Surgical and Radiation Oncology Clinical Trials Access Program (SROCTAP) which conducts clinical trials at several medical centers within Kaiser Permanente Southern California (KPSC). Dr Vasilev has been involved in clinical research for over 37 years associated with four academic medical centers (USC, UCLA, UCI and City of Hope), the private sector and within Kaiser Permanente. The scope of investigation and responsibilities has included grant applications, clinical and administrative oversight of translational and multiple investigator initiated, industry sponsored, and cooperative group clinical trials. Trials have encompassed investigational agents, devices and integrative approaches such as nutrigenomics. Upon joining Kaiser Permanente in 1998 he initiated a local program to introduce Gynecologic Oncology Group clinical trials. Within several years this program grew to include surgical, radiation, chemo and biological trials spanning surgical, gynecologic, urologic, head and neck, neurologic oncology departments in several Kaiser Permanente medical centers. The program currently supports 15 sub-investigators and enrolls patients into 20 clinical trials. Currently he is Professor and Chairman of Gynecologic Oncology Research, John Wayne Cancer Institute at Providence Saint John’s Health Center in Santa Monica California. At this location he is initiating clinical trials and translational research in gynecologic oncology.

Research Interest

He served as a Visiting Professor at National Chao-tung University and Associate Professor at the University of Central Florida, Founder & CEO of Nasdaq-listed companies, He holds over 40 patents and is the inventor (US patents, 1992, 2000) of flying-spot LASIK procedure currently used in eye hospitals worldwide. He has ublished over 55 book chapters and over 200 peer-review journal papers including about 80 SCI-indexed. His awards include WHOs WHO in Leading American Executives, Model of oversea Chinese Young Entrepreneur and Fellow of American Society of Laser Surgery & Medicine.

Research Interest

Research Interest

Hunis graduated in 1973 from the University of La Plata School of Medicine, Argentina. Postgraduate training in Internal Medicine was completed at Ramos Mejia Hospital in Buenos Aires, Argentina. Fellowships in Medical Oncology were completed at the Universidad del Salvador and Chair of Oncology based at the Central Military Hospital, Buenos Aires, Argentina. He completed his oncology fellowship at the Miami Cancer Institute, Division of Medical Oncology, Miami, Florida, USA. Dr. Huñis became board certified in Oncology in 1978. In 1996, he was a member of the first group of certified oncologists with the academic, scientific and institutional endorsement of the Argentine Association of Medical Oncology Cancer Society and the Argentine. In 2004 obtained the recertification of the National Academy of Medicine.

Research Interest

Adel Tahseen Aref was graduated from Ain Shams Medical School, Cairo, Egypt, with grade excellent with honour in 2003. I had one year as intern at Ain Shams University hospitals. In 2005, I started my residency training at the Clinical Oncology Department, Ain Shams University hospitals. I got my master degree in Clinical Oncology in 2008. I worked as Medical Oncology specialist for one year in Cairo, and then I travelled to Dubai, UAE, where I worked as medical oncology specialist for 5 years at Dubai Hospital. In 2010 I got my Medical Oncology certification from the European Society of Medical Oncology (ESMO). In 2013, I got my Medical Oncology Speciality certification from the Royal College of Physician, UK. In 2015, I moved to Kingdom of Bahrain where I worked as senior medical oncology specialist for one year. In 2012, I established ‘MedicalSurveys-17 Research Group’, with a group of young oncologist who are working in different institutes in the Middle East region. We had a number of projects, which aimed to screen the oncological clinical practice in the Middle East. In 2014, we had a conjoint work with the support of the European School of Oncology (ESO), to screen the clinical practice of breast cancer management in the MENA region and to what extent there is a need for regional guidelines for breast cancer management. In 2016 I was awarded PhD scholarship from the University of Adelaide.In June 2016, I joined the Lipid and prostate cancer research group to start my PhD project at the South Australian Health and Medical Research Institute (SAHMRI). My PhD research project is about the effect of obesity and abnormal metabolic profile on prostate cancer incidence and aggressiveness

Research Interest

Piyush Vyas is a board certified clinical Oncologist , presently undergoing his next training in Clinical haematology. Dr Piyush Vyas has published many articles in peer reviewed journals, is /was member of many professional societies like ESMO, ASCO , AACR, Polish Society of Clinical Oncology.Dr Piyush Vyas is a clinician and also an academician teach undergraduate and postgraduate students at Medical University of Warsaw, Poland. Having had passed the ESMO(European Society of Medical Oncology) exam has shown his expertise on Oncological and haematological malignancies.His main interest is in haematological and oncological malignancies. His group was the first to administer chemotherapy in a patient with metastatic duodenal cancer with co-existent immune thrombocytopenic Purpura."Dr Piyush Vyas has published many articles on Hepatocellular carcinoma, his special interest topic. He has the credit to publish the first case study of longest surviving patient with adenocarcinoma of lung treated with EGFR kinase inhibitor" Erlotinib". Not only is he an excellent clinician appreciated worldwide , but also has published many review articles, case studies , presented posters at international conferences

Research Interest

Research Interest

I was the acting head of division of Hematology and Oncology in Specialized Medical Centre (SMC). Since April 2009, I have created and built the division. My target is to be a European Society of Medical Oncology certified division. My team got through many obstacles with the support of the higher management; such as place allocation, training competent staff and drug shortage. One of the important achievements was to overcome the worldwide drug shortage and purchase the appropriate medical equipments. In addition to that, I was the assistant director of the quality department; I left it for a while to focus on the expansion of the division, to be back again this year. The goal is to provide the best services and quality of care to our community. I am also the leader of two teams, blood bank services and venous thrombo-embolism prophylaxis. Thanks to my teams, we successfully accomplished the highest Canadian accreditation and its targets. For 5 years in Quality, I have acquired great experience and knowledge about patient safety and best quality of care; and still ongoing. SMC is the first private institution to have an Institutional review board. I am currently developing a team from the division Hematology and Oncology to make grounds for future clinical research and scientific recognition. I am very interested in clinical research and its implications on the progress of the division and the additional care provided to our patients. I am included in clinical laboratory, pharmacy and medical committees to help advance in the methods and techniques how we administer the best of healthcare.

Research Interest

Research Interest

Dr Luis Ubillos is an Associate Professor of Medical Oncology at Hospital de Clinicas in Montevideo, Uruguay. He joined the University in 2010, as associate profesor in medical oncology. He devotes her time between clinical, teaching and research activities. His research interests are cancer immunotherapy and traslational research. He is committed to global education and actively collaborates with international scientific associations in educational activities around the world in several countries.

Research Interest

Research Interest